Skip to main content
. 2018 Nov 23;8:17297. doi: 10.1038/s41598-018-35602-1

Figure 1.

Figure 1

Enzyme selectivity of CKD-506 & Pharmacokinetic profile of CKD-506. The selectivity of CKD-506 was analyzed based on HDAC enzyme inhibition and protein acetylation. (A) After single intraperitoneal injection of CKD-506, blood samples were collected at the indicated time points. The plasma concentration of CKD-506 was analyzed. All the data were presented as mean ± SD. Upper panel: plasma concentration – time plot of CKD-506; Lower table: pharmacokinetic parameters of CKD-506. (B) The enzyme activity of HDAC family members with the indicated concentration of CKD-506 (log of molar concentration; Log M) was analyzed and plotted. The Y-axis represents the percentage of enzymatic activity normalized to the enzyme activity without CKD-506. (C) The HDAC6 enzyme selectivity of CKD-506 in human PBMC was analyzed based on the acetylation of α tubulin, one of the major target proteins of HDAC6, and the acetylation of histone H4 which is not a target protein of other HDAC isozymes. LBH-589 is a pan HDAC inhibitor, a positive control for the induction of histone H4 acetylation (the chemicals were treated for 4 hr.). Samples were derived from the same experiment, and blots were processed in parallel. Full-length blots are presented in Supplementary Fig. 1. T1/2: elimination half-life; hr: hour; Tmax: time to maximum plasma concentration; Cmax: maximum plasma concentration; AUC0–24hr: area under the curve from time zero to 24 hr; AUCinf: area under the curve from time zero to infinity (extrapolated data); i.p.: intraperitoneal.